Affiliation:
1. Univ. Bordeaux, INSERM CIC
2. Caen University Hospital, UNICAEN
3. APHP CHU Bicêtre – Bicêtre
4. CHU Grenoble
5. Astra-Zeneca
Abstract
Abstract
Background
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal disease (CVRD) manifestations for type 2 diabetes. The incidence of the first occurring CVRD manifestation and cumulative hospitalization costs of each CVRD manifestation are not well known for type 2 diabetes without CVRD history.
Methods
A cohort study of all type 2 diabetes free of CVRD as of January 1st 2014, was identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurring CVRD manifestation was estimated using the cumulative incidence function, with death as a competing risk. Cumulative hospitalization costs of each CVRD manifestations were estimated from the perspective of all payers.
Results
From about 2 million type 2 diabetes without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women and 7% with microvascular complications history. The cumulative incidence of a first CVRD manifestation was 15.3% after 5 years of follow-up with a constant linear increase over time for all CVRD manifestations: The most frequent was CKD representing 40.6% of first occurred CVRD manifestation, followed by HF (23.0%), then PAD (13.5%), stroke (13.2%) and MI (9.7%). HF and CKD together reached about one patient out of ten after 5 years and represented 63.6% of first CVRD manifestations. The 5-year global cost of all CVRD hospitalizations was 3.9 billion euros (B€), i.e. 2,450€ per patient of the whole cohort, with an exponential increase over time for each specific CVRD manifestation. The costliest was CKD (2.0 B€), followed by HF (1.2 B€), then PAD (0.7 B€), stroke (0.6 B€) and MI (0.3 B€).
Conclusions/interpretation
While MI, stroke and PAD remain classic major risks of complications for CVRD-free type 2 diabetes, HF and CKD nowadays represent individually a higher risk and cost than each of these classic manifestations, and jointly represents a risk and a cost twice as high as of these three classic manifestations all together. This should encourage the development of specific HF and CKD preventive strategies.
Publisher
Research Square Platform LLC
Reference41 articles.
1. Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th ed. Brussels: International Diabetes Federation; 2021.
2. Diabetes. n.d. https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed November 4, 2022).
3. Diabetes mellitus, fasting glucose, and risk of cause-specific death;Rao Kondapally Seshasai S;N Engl J Med,2011
4. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II;Beckman JA;Eur Heart J,2013
5. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD);Members ATF;Eur Heart J,2013